中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 05-12 16:08:03

5.780

+0.120

+2.12%

最高5.830	最低5.650	成交量1.19亿
今开5.700	昨收5.660	日振幅3.18%
总市值1,083亿	流通市值1,083亿	总股本187.45亿
成交额6.84亿	换手率0.63%	流通股本187.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.78,"timestamp":1778573283002,"preClose":5.66,"halted":0,"volume":118801222,"delay":0,"changeRate":0.021201413427561856,"floatShares":18745000000,"shares":18745000000,"eps":0.14963863295598667,"marketStatus":"未开盘","change":0.12,"latestTime":"05-12 16:08:03","open":5.7,"high":5.83,"low":5.65,"amount":684182096,"amplitude":0.031802,"askPrice":5.78,"askSize":335000,"bidPrice":5.76,"bidSize":374000,"shortable":3,"etf":0,"ttmEps":0.14963863295598667,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":0,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.66,"dividendRate":0.017827,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"volumeRatio":1.8573389558148155,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.4186,"impliedVolPercentile":0.4494},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2634683261","title":"港股异动 | 中国生物制药(01177)涨超3% 高盛指引入bepirovirsen疗法有望升级公司肝炎产品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2634683261","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634683261?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:43","pubTimestamp":1778564586,"startTime":"0","endTime":"0","summary":"根据协议，公司将利用其领先的肝炎基础设施，全面负责进口、分销、医院准入及推广，并将全数录入bepirovirsen在中国的销售。报告指出，bepirovirsen作为针对慢性乙肝功能性治愈的同类首创疗法，策略上契合中国7,500万慢性乙肝患者的治疗重点，有望升级中国生物制药的肝炎产品组合。该行估计bepirovirsen的潜在销售额高峰约为50亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1868837136.USD","LU2750360997.AUD","LU1894683348.USD","IE00B19Z3581.USD","LU2471134952.CNY","01177","IE00BZ08YS42.EUR","BK4588","LU0251131958.USD","LU1668664300.SGD","LU0106831901.USD","BK4127","LU2237443978.SGD","LU2237443622.USD","LU1868836914.USD","LU1791807156.HKD","LU2237443382.USD","IE00BZ08YR35.GBP","IE0004086264.USD","LU1894683264.USD","LU0251142724.SGD","BK4552","BK4504","LU2265009873.SGD","IE00BFXG1179.USD","GSX","LU1868836591.USD","LU0096364046.USD","IE0004091025.USD","LU2237443895.HKD","VXUS","BK1521","BK4533","LU0061475181.USD","LU1868837300.USD","BK4516","LU0742534661.SGD","IE00B19Z3B42.SGD","LU1804176565.USD","IE00BZ08YT58.USD","LU2237443549.SGD","LU2471134523.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU0345770308.USD","HK0000165453.HKD","BK4585","IE0002270589.USD","LU2471134796.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634338289","title":"中国生物制药涨超4%：牵手GSK合作乙肝临床治愈明星产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2634338289","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634338289?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:58","pubTimestamp":1778500680,"startTime":"0","endTime":"0","summary":"全球首款有望最快实现乙肝功能性治愈的重磅药物被中国生物制药收入囊中！5月11日，中国生物制药（1177.HK）正式宣布，核心子公司正大天晴药业集团与知名跨国药企葛兰素史克（LSE/NYSE：GSK）达成独家战略合作，将加速一款名为bepirovirsen的药物在中国的上市进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733296932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733296932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4588","GSK","HK0000165453.HKD","BK4007","GSKH","BK1589","LU1829250122.USD","IE00BZ08YS42.EUR","BK4532","BK4585","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","01177","BK1521","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172853340","title":"中国生物制药回购181.00万股股份，总额约1,001.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172853340","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172853340?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:26","pubTimestamp":1778487975,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年5月11日公告称，公司当日在香港联交所场内回购股份181.00万股，约占其已发行股本的0.01%。本次回购价格介乎每股港币5.45至港币5.58之间，合计耗资约1,001.49万港元。回购完成后，公司已发行股本仍维持在18,745,367,230股，库藏股数尚无变动。根据该授权，公司可回购股份总数为1,876,071,723股，截至目前已在香港联交所或其他证券交易所累计回购股份42,580,000股，占授权通过当日已发行股本的0.227%。公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药回购181.00万股股份，总额约1,001.49万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634030406","title":"中国生物制药(01177)5月11日耗资约1001.49万港元回购181万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634030406","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634030406?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:23","pubTimestamp":1778487795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)公布，2026年5月11日耗资约1001.49万港元回购181万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1589","BK1515","BK1191","01177","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634010474","title":"港股异动 | 中国生物制药(01177)午后涨超4% 正大天晴与葛兰素史克合作乙肝治愈重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2634010474","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634010474?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:35","pubTimestamp":1778477746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药午后涨超4%，截至发稿，涨4.05%，报5.65港元，成交额2.78亿港元。消息面上，中国生物制药午间公告，集团附属公司正大天晴与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","GSK","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","BK4007","BK1515","BK4585","BK1521","GSK.UK","HK0000165453.HKD","VXUS","01177","IE00BZ08YS42.EUR","GSKH","LU1829250122.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634147972","title":"中国生物制药(01177)与葛兰素史克达成独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2634147972","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634147972?lang=zh_cn&edition=full","pubTime":"2026-05-11 12:26","pubTimestamp":1778473605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司与葛兰素史克达成一项独家战略合作，加速bepirovirsen在中国内地的上市进程。根据协议条款，正大天晴将在初始5.5年合作期内，按照约定的供应条款向GSK采购bepirovirsen。通过持续深化与全球领先药企的战略合作，集团进一步巩固了作为MNC在中国首选合作伙伴的行业领先地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1589","GSKH","BK4585","01177","BK1191","IE00BZ08YR35.GBP","HK0000165453.HKD","GSK.UK","BK1515","LU1829250122.USD","BK4007","BK4532","GSK","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159683910","title":"中国生物制药旗下子公司将负责Bepirovirsen在华销售与分销；相关收入将由该子公司确认","url":"https://stock-news.laohu8.com/highlight/detail?id=1159683910","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159683910?lang=zh_cn&edition=full","pubTime":"2026-05-11 12:14","pubTimestamp":1778472883,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其旗下的一家子公司将负责管理Bepirovirsen在中国市场的销售与分销业务。根据安排，与此药物相关的所有销售收入将直接由该运营子公司进行确认。Bepirovirsen是一种用于治疗慢性乙型肝炎的潜在新药，由葛兰素史克研发。这一举措标志着中国生物制药在整合其创新药产品管线与商业化能力方面迈出了重要一步。公司预计，通过专业化的销售与分销管理，将有助于提升Bepirovirsen的市场渗透率，并为公司带来可持续的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.SGD","01177","SG9999001176.USD","LU1015430645.USD","LU0971552673.USD","LU1098665638.USD","IE00BZ08YS42.EUR","BK1191","SGXZ57979304.SGD","GSK.UK","IE00BWDBJ516.SGD","LU1228905037.USD","LU1983299246.USD","LU0211331839.USD","LU1481600234.SGD","LU1035777561.USD","BK1521","LU1064927863.SGD","IE00BZ08YT58.USD","LU1046248800.SGD","BK1515","LU0985481810.HKD","LU1202635105.USD","LU2646069778.SGD","LU0557290698.USD","LU1309081286.SGD","LU0306806265.USD","SG9999013999.USD","LU0321505868.SGD","LU0203345920.USD","LU0161305163.EUR","LU0203347892.USD","LU0225771236.USD","LU1400636657.SGD","LU0321505439.SGD","LU1302929846.USD","LU0306807586.USD","LU1670756490.USD","BK1589","LU0109981661.USD","LU0058720904.USD","LU1400636491.USD","LU2468319806.SGD","BK5011","LU1228905540.USD","IE0034235071.USD","LU0987226296.USD","LU0289739699.SGD","LU1481599808.USD","LU1487256676.USD","LU0575583348.USD","IE00BZ08YR35.GBP","LU2089984988.USD","HK0000165453.HKD","IE00B3T34201.USD","LU0225283273.USD","LU0971552830.HKD","LU1400636574.HKD","LU0225284248.USD","LU1645745479.HKD","IE00BQJZX424.USD","LU0545562505.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155061329","title":"中国生物制药与葛兰素史克或在中国以外研发管线探索更广泛合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1155061329","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155061329?lang=zh_cn&edition=full","pubTime":"2026-05-11 12:11","pubTimestamp":1778472675,"startTime":"0","endTime":"0","summary":"中国生物制药与葛兰素史克可能就中国以外的研发管线，探索更为广泛的合作。这一潜在的合作动向，预示着两家公司或将整合各自在研发领域的优势资源，共同拓展国际市场。此举可能涉及创新药物的研发与商业化，旨在加速产品管线的全球布局。双方的合作若能达成，将进一步提升其在全球生物医药领域的竞争力与影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0545562505.USD","LU0321505439.SGD","LU0971552673.USD","LU0971552830.HKD","LU1983299246.USD","SGXZ57979304.SGD","BK5011","BK1521","GSK.UK","LU1309081286.SGD","LU0058720904.USD","LU1064927863.SGD","LU1400636657.SGD","LU0203347892.USD","LU1046248800.SGD","LU1098665638.USD","LU0109981661.USD","IE00BZ08YS42.EUR","LU0225283273.USD","LU1302929846.USD","LU0306806265.USD","LU0557290698.USD","LU1228905540.USD","LU0225284248.USD","LU0321505868.SGD","BK1515","LU1400636491.USD","LU1645745479.HKD","LU1670756490.USD","LU0987226296.USD","LU2089984988.USD","BK1589","LU2646069778.SGD","LU1481599808.USD","HK0000165453.HKD","LU1228905037.USD","IE00BZ08YT58.USD","LU0211331839.USD","LU1015430645.USD","IE00BWDBJ516.SGD","LU1400636574.HKD","LU0225771236.USD","LU0306807586.USD","LU0985481810.HKD","SG9999001176.SGD","LU0575583348.USD","LU1035777561.USD","IE00BZ08YR35.GBP","LU1481600234.SGD","IE0034235071.USD","LU1202635105.USD","SG9999013999.USD","LU0203345920.USD","IE00B3T34201.USD","LU0161305163.EUR","01177","LU0289739699.SGD","LU1487256676.USD","LU2468319806.SGD","SG9999001176.USD","IE00BQJZX424.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634617427","title":"中国生物制药(01177)股东将股票存入花旗银行 存仓市值32.76亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634617427","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634617427?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:11","pubTimestamp":1778458310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月8日，中国生物制药(01177)股东将股票存入花旗银行，存仓市值32.76亿港元，占比3.2%。中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司联合开发的国家1类创新药M701“CD3/EpCAM 双特异性抗体”用于治疗晚期上皮性恶性肿瘤导致的恶性腹水 (MA)，已向中国国家药品监督管理局药品审评中心(CDE)递交新药上市申请，并获得受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0203347892.USD","LU0477156953.USD","LU2360032135.SGD","IE00BZ08YT58.USD","LU0072461881.USD","LU0106831901.USD","LU0980610538.SGD","BK1521","LU1244550221.USD","LU0162691827.USD","LU2417539215.USD","LU0648001328.SGD","LU1244550494.USD","LU0130517989.USD","LU0314106906.USD","LU2456880835.USD","BK1191","BK4534","LU2462157665.USD","IE00BZ08YS42.EUR","LU0320765646.SGD","LU0130102774.USD","LU1201861249.SGD","HK0000165453.HKD","BK1515","LU2236285917.USD","LU1791807156.HKD","BK4566","IE00BSNM7G36.USD","LU1267930227.SGD","LU1244550577.SGD","BK4207","LU0052756011.USD","BK4559","LU1366192091.USD","LU0098860793.USD","LU2125154935.USD","LU0128525689.USD","LU1506573853.SGD","BK4588","IE00BZ08YR35.GBP","LU0170899867.USD","LU0203345920.USD","BK4585","LU2125154778.USD","LU1162221912.USD","BK1589","01177","LU1668664300.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634496203","title":"中国生物制药于5月8日斥资1005.5万港元回购186万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634496203","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634496203?lang=zh_cn&edition=full","pubTime":"2026-05-09 10:05","pubTimestamp":1778292300,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　中国生物制药（01177）发布公告，于2026年5月8日斥资1005.5万港元回购186万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-09/doc-inhxhcxm7012112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YR35.GBP","BK1589","01177","BK1191","IE00BZ08YT58.USD","BK1521","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180910672","title":"中国生物制药5月8日回购186万股，耗资约1,005.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180910672","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180910672?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:52","pubTimestamp":1778230338,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年5月8日发布公告，披露当日通过香港联交所场内回购公司普通股1,860,000股，约占已发行股本的0.01%。本次回购价格介乎每股港币5.38元至5.44元，合计耗资约港币1,005.50万。根据公告，本次回购完成后，公司已发行股本仍为18,745,367,230股，库藏股数为零。本次回购后，新股发行及库藏股出售或转让的暂止期将截至2026年6月7日。公司在公告中确认已遵守香港联交所相关上市规则及其他适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药5月8日回购186万股，耗资约1,005.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144457","title":"智通港股解盘 | AI热潮从硬件扩散到应用端 马斯克概念受到追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633144457?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:59","pubTimestamp":1778155199,"startTime":"0","endTime":"0","summary":"声明同时警告说，如果乌方在胜利日期间对莫斯科发动袭击，俄军将对基辅市中心实施大规模导弹打击，并呼吁平民及外国外交人员撤离基辅。希望俄乌双方保持克制，否则基辅陷入大的打击对市场会构成压力。这是自2022年11月以来连续第18个月增持黄金。当地时间周三，费城半导体指数刷新2000年3月9日以来最强五周滚动表现，该指数此期间累计涨幅超50%。中国高阶智驾仿真市场占有率达53.5%的头部企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","BK1589","AIPO","LU2097828805.USD","SG9999015978.USD","BK1161","IE00BGHQDM52.EUR","01177","CHAT","SG9999004220.SGD","LU2097828557.USD","LU2097828714.EUR","IE00BMCWC346.EUR","LU2097828474.EUR","03933","BK1191","01801","UFO","LU0455707207.USD","BK1583","IE00BZ08YT58.USD","LU0502904849.HKD","LU2242644610.SGD","LU2328871848.SGD","DXYZ","BK1521","IE00BZ08YS42.EUR","BK1515","VXUS","LU2097828631.EUR","BK4588","IE00BVYPNQ40.USD","IE00BYV24P56.USD","BK1593","BK4585","03692","00867","AGIX","HK0000165453.HKD","ARTY","SG9999015945.SGD","LU2488822045.USD","SG9999015952.SGD","IE00BVYPNP33.GBP","LU1969619763.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150526654","title":"中国生物制药：5月7日回购1,850,000股股份，总额约1,004.72万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150526654","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150526654?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:02","pubTimestamp":1778144520,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年5月7日公告，当日公司在香港联交所场内回购普通股共1,850,000股，占已发行股本约0.01%，每股回购价介乎港币5.39港元至5.46港元，总耗资10,047,165港元。公告同时显示，公司购回授权于2025年6月10日获得通过，授权购回的股份总数为1,876,071,723股；截至目前，公司已在香港联交所或其他证券交易所合计购回38,910,000股，占授权总额约0.207%。公司已确认本次回购符合香港联交所证券上市规则及相关法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：5月7日回购1,850,000股股份，总额约1,004.72万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119585","title":"中国生物制药(01177)5月7日斥资1004.72万港元回购185万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119585","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119585?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:56","pubTimestamp":1778144192,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年5月7日，该公司斥资1004.72万港元回购185万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","BK1521","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177407251","title":"中国生物制药M701双特异性抗体新药申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1177407251","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177407251?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:38","pubTimestamp":1778143138,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。\nM701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","BK1521","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633811642","title":"中国生物制药：M701双抗新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633811642","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633811642?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:38","pubTimestamp":1778143080,"startTime":"0","endTime":"0","summary":"南财智讯5月7日电，中国生物制药（01177.HK）发布自愿公告，公司附属公司正大天晴药业集团股份有限公司联合开发的国家1类创新药M701“CD3/EpCAM双特异性抗体”，用于治疗晚期上皮性恶性肿瘤导致的恶性腹水，已向国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073730113816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1191","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1515","BK1589","IE00BZ08YT58.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633164997","title":"港股公告掘金 | 东方证券拟通过发行A股股份及支付现金方式购买上海证券100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2633164997","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633164997?lang=zh_cn&edition=full","pubTime":"2026-05-07 09:00","pubTimestamp":1778115646,"startTime":"0","endTime":"0","summary":"重大事项：石四药集团(02005)取得甲磺酸多沙唑嗪缓释片(4mg)等药品的生产注册批件中国生物制药(01177)：库莫西利胶囊“CDK2/4/6抑制剂”一线治疗乳腺癌新适应症获批上市佰金生命科学(01466)附属与扶摇元气订立策略合作框架协议 开展临床细胞治疗领域的策略合作石四药集团(02005)：全量程C反应蛋白(hsCRP+常规CRP)检测试剂盒及血清淀粉样蛋白A/C反应蛋白(SAA/CRP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK0012","IE00BZ08YT58.USD","161027","BK1227","BK4588","399300","VXUS","IE00BZ08YR35.GBP","BK0028","BK1191","IE00BZ08YS42.EUR","BK0188","BK1515","BK1589","HK0000165453.HKD","BK0183","01177","BK4585","159982","01466","LU2460026573.USD","BK1147","BK0276","BK1521","BK1564","03958","600958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177165","title":"中国生物制药(01177)：克非奇拜单抗“CCR8单抗”二线治疗胃癌Ⅲ期注册临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177165","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633177165?lang=zh_cn&edition=full","pubTime":"2026-05-07 06:40","pubTimestamp":1778107201,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药克非奇拜单抗“CCR8单抗”联合PD-1抑制剂二线治疗CCR8阳性的局部晚期或转移性胃癌╱胃食管交界处腺癌的III期注册临床试验，已顺利完成首例患者入组。PD-1/ PD-L1免疫治疗在二线胃癌中，仅能使少数MSI-H/dMMR患者获益，绝大多数患者仍面临原发或继发性耐药的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1589","BK1515","BK1521","HK0000165453.HKD","01177","IE00BZ08YS42.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142563681","title":"中国生物制药Culmerciclib胶囊获国家药监局批准用于HR+/HER2-晚期乳腺癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1142563681","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142563681?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:03","pubTimestamp":1778058182,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其创新药物Culmerciclib胶囊已正式获得中国国家药品监督管理局（NMPA）批准，用于激素受体阳性/人表皮生长因子受体2阴性（HR+/HER2-）晚期乳腺癌的一线治疗。这一重要监管突破标志着该药物在中国正式进入临床应用阶段，为晚期乳腺癌患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01177","IE00BZ08YR35.GBP","BK1589","IE00BZ08YS42.EUR","BK1515","BK1521","IE00BZ08YT58.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633883701","title":"中国生物制药(01177)：库莫西利胶囊“CDK2/4/6抑制剂”一线治疗乳腺癌新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2633883701","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633883701?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:01","pubTimestamp":1778058070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主开发的国家1类创新药库莫西利胶囊“CDK2/4/6抑制剂”已获得中国国家药品监督管理局的上市批准，联合氟维司群用于激素受体阳性、人表皮生长因子受体2 阴性的局部晚期或转移性乳腺癌患者的初始内分泌治疗。这是库莫西利获批上市的第2项适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1191","IPOS","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0625},{"period":"1month","weight":-0.0236},{"period":"3month","weight":-0.1537},{"period":"6month","weight":-0.2157},{"period":"1year","weight":0.5259},{"period":"ytd","weight":-0.0647}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.0337},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.478261,"avgChangeRate":0.021296},{"month":5,"riseRate":0.73913,"avgChangeRate":0.04435},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}